Who are Conditioning regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, Oxaliplatin;Capecitabine, Chemotherapy+Pembrolizumab., Pegylated liposomal doxorubicin hydrochloride, Methoxsalen+ECP, chemotherapy plus p53.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/conditioning-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Conditioning regimen — Competitive Intelligence Brief

Conditioning regimen (Conditioning regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy. Area: Oncology.

phase 2 Chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Conditioning regimen (Conditioning regimen) — Assistance Publique - Hôpitaux de Paris. This conditioning regimen involves a combination of chemotherapy and radiation therapy to prepare the body for a bone marrow transplant.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Conditioning regimen TARGET	Conditioning regimen	Assistance Publique - Hôpitaux de Paris	phase 2	Chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Oxaliplatin;Capecitabine	Oxaliplatin;Capecitabine	Hebei Medical University	marketed	Platinum-based chemotherapy combination; antimetabolite	DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU)
Chemotherapy+Pembrolizumab.	Chemotherapy+Pembrolizumab.	Tang-Du Hospital	marketed	Chemotherapy + PD-1 inhibitor combination	PD-1 (programmed death receptor 1); chemotherapy targets DNA
Pegylated liposomal doxorubicin hydrochloride	Pegylated liposomal doxorubicin hydrochloride	M.D. Anderson Cancer Center	marketed	Anthracycline chemotherapy (liposomal formulation)	Topoisomerase II, DNA
Methoxsalen+ECP	Methoxsalen+ECP	M.D. Anderson Cancer Center	marketed	Photochemotherapy agent
chemotherapy plus p53	chemotherapy plus p53	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Combination chemotherapy with p53 gene therapy	p53 tumor suppressor protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy class)

University Hospital, Rouen · 2 drugs in this class
Sun Yat-sen University · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
Delcath Systems Inc. · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Prof. Dr. med. Claus Rödel · 1 drug in this class
Prothena Biosciences Ltd. · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Conditioning regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/conditioning-regimen. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab